The Mantoux test will become redundant because once the automated "in tube" systems become common place over the next few years the comparative cost of conducting the skin test will be the prohibitive factor. Remember it is labour costs not the cost of each test that is the biggest overhead for agencies. Then add the costs of false positives and inappropriate treatments.
The number of manufacturers producing the TST has already been reduced. When the writing is on the wall the manufacturers will phase out production on an economic basis and justify it on a scientific basis.
Routine Mantoux testing of the general population was phased out years ago so the market for the TST had already suffered a major blow previously.
Honestly, I realy expect a major multi-national pharmaceutical/diagnostics company to launch a takeover bid as soon as Cellestis receive FDA approval for the "in tube" product/procedure.
CST Price at posting:
0.0¢ Sentiment: Hold Disclosure: Held
